Home / Clindamycin / United States
US ATC J01FF01 · updated 2 Nov 2026
Clindamycin shortage in United States
Is there a Clindamycin shortage in United States?
Yes. As of 2 Nov 2026, 6 Clindamycin products are reported short in United States, the first since 21 Mar 2023. No return date has been given. Main reason: manufacturing problem.
Also short in Canada, France, Italy, Ireland, Belgium, Switzerland, Czechia, Australia. All countries.
Affected products in United States
| Country | Product | Company | Since | Expected back | Reason |
|---|---|---|---|---|---|
| US | Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-02) limited | Sagent Pharmaceuticals | 21 Mar 2023 | not given | Manufacturing problem Discontinuation of the manufacture of the drug |
| US | Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-04) discontinuation | Sagent Pharmaceuticals | 21 Mar 2023 | not given | Manufacturing problem Discontinuation of the manufacture of the drug |
| US | Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-06) limited | Sagent Pharmaceuticals | 21 Mar 2023 | not given | Manufacturing problem Discontinuation of the manufacture of the drug |
| US | Cleocin Hydrochloride, Capsule, 150 mg (NDC 0009-0225-02) discontinuation | Pfizer Inc. | 25 Feb 2026 | not given | Not stated |
| US | Cleocin Hydrochloride, Capsule, 300 mg (NDC 0009-0395-14) discontinuation | Pfizer Inc. | 25 Feb 2026 | not given | Not stated |
| US | Cleocin Hydrochloride, Capsule, 75 mg (NDC 0009-0331-02) discontinuation | Pfizer Inc. | 25 Feb 2026 | not given | Not stated |
Source
U.S. Food and Drug Administration (FDA), Drug Shortages via openFDA. Official list. Shortages the FDA lists as current, plus products to be discontinued; one row per package (NDC).